Entrada Therapeutics Return On Assets Over Time
| TRDA Stock | USD 18.80 0.75 4.16% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Entrada Therapeutics Performance and Entrada Therapeutics Correlation. Entrada |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entrada Therapeutics. If investors know Entrada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entrada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.44 | Revenue Per Share 6.074 | Quarterly Revenue Growth (0.55) | Return On Assets 0.0695 | Return On Equity 0.1642 |
The market value of Entrada Therapeutics is measured differently than its book value, which is the value of Entrada that is recorded on the company's balance sheet. Investors also form their own opinion of Entrada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Entrada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entrada Therapeutics' market value can be influenced by many factors that don't directly affect Entrada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entrada Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Entrada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entrada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Return On Assets Analysis
Compare Entrada Therapeutics and related stocks such as Molecular Partners, Pmv Pharmaceuticals, and Monte Rosa Therapeutics Return On Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MOLN | 0.0649 | 0.0649 | 0.0649 | 0.0649 | (0.0118) | (7.0E-4) | (0.1011) | (0.1761) | (0.2387) | (0.3458) | (0.3347) | (0.3694) | 0.4494 | (0.3125) | (0.3) |
| PMVP | (0.2764) | (0.2764) | (0.2764) | (0.2764) | (0.2764) | (0.2764) | (0.2764) | (0.2764) | (0.2764) | (0.2461) | (0.0942) | (0.1745) | (0.2712) | (0.2735) | (0.29) |
| GLUE | (0.7226) | (0.7226) | (0.7226) | (0.7226) | (0.7226) | (0.7226) | (0.7226) | (0.7226) | (0.7226) | (0.7226) | (0.7304) | (0.1964) | (0.3056) | (0.4456) | (0.47) |
| VIGL | (1.1285) | (1.1285) | (1.1285) | (1.1285) | (1.1285) | (1.1285) | (1.1285) | (1.1285) | (1.1285) | (1.1285) | (1.1285) | (0.4222) | (0.338) | (0.5867) | (0.62) |
| THRD | (1.5187) | (1.5187) | (1.5187) | (1.5187) | (1.5187) | (1.5187) | (1.5187) | (1.5187) | (1.5187) | (1.5187) | (1.5187) | (0.2292) | (0.1263) | (0.111) | (0.12) |
| CGEM | (0.4096) | (0.4096) | (0.4096) | (0.4096) | (0.4096) | (0.4096) | (0.4096) | (0.4096) | (0.4096) | (0.1995) | (0.2368) | (0.1488) | 0.1982 | (0.3163) | (0.3) |
| EWTX | (0.3865) | (0.3865) | (0.3865) | (0.3865) | (0.3865) | (0.3865) | (0.3865) | (0.3865) | (0.3865) | (0.3865) | (0.13) | (0.1477) | (0.0419) | (0.2946) | (0.31) |
| RLYB | (0.8158) | (0.8158) | (0.8158) | (0.8158) | (0.8158) | (0.8158) | (0.8158) | (0.8158) | (0.8158) | (0.8158) | (0.1757) | (0.258) | (0.3685) | (0.6449) | (0.68) |
| CRNX | (0.4777) | (0.4777) | (0.4777) | (0.4777) | (0.4777) | (0.4777) | (0.4777) | (0.5871) | (0.1582) | (0.3799) | (0.3972) | (0.304) | (0.4542) | (0.3377) | (0.35) |
| CNTA | (0.9423) | (0.9423) | (0.9423) | (0.9423) | (0.9423) | (0.9423) | (0.9423) | (0.9423) | (0.9423) | (0.9423) | (0.9423) | (0.6065) | (0.4866) | (0.4194) | (0.44) |
| IRON | (0.3904) | (0.3904) | (0.3904) | (0.3904) | (0.3904) | (0.3904) | (0.3904) | (0.3904) | (0.3904) | (0.3904) | (0.3904) | (0.4437) | (0.2302) | (0.2077) | (0.22) |
| LRMR | (0.3112) | (0.3112) | (0.3112) | (0.3112) | (0.3112) | (0.3928) | (0.4397) | (0.4931) | (0.504) | (4.4476) | (0.4043) | (0.6395) | (0.2704) | (0.3851) | (0.4) |
| PEPG | (0.321) | (0.321) | (0.321) | (0.321) | (0.321) | (0.321) | (0.321) | (0.321) | (0.321) | (0.321) | (0.1768) | (0.1899) | (0.3178) | (0.5496) | (0.58) |
| TYRA | (7.6856) | (7.6856) | (7.6856) | (7.6856) | (7.6856) | (7.6856) | (7.6856) | (7.6856) | (7.6856) | (7.6856) | (0.5817) | (0.0852) | (0.1943) | (0.3061) | (0.32) |
| PHVS | (0.7939) | (0.7939) | (0.7939) | (0.7939) | (0.7939) | (0.7939) | (0.7939) | (0.7939) | (0.7939) | (0.3905) | (0.257) | (0.2015) | (0.4551) | (0.253) | (0.27) |
| GNTA | (0.2158) | (0.2158) | (0.2158) | (0.2158) | (0.2158) | (0.2158) | (0.2158) | (0.2158) | (0.2158) | (0.2158) | (0.3203) | (0.1389) | (0.1084) | (0.5211) | (0.55) |
| OPT | (0.168) | (0.214) | (0.2897) | (0.3207) | (0.2207) | (0.3816) | (0.1095) | (0.3668) | (0.5552) | (0.2242) | (0.3297) | (1.4657) | (1.4298) | (1.1666) | (1.11) |
Entrada Therapeutics and related stocks such as Molecular Partners, Pmv Pharmaceuticals, and Monte Rosa Therapeutics Return On Assets description
A profitability ratio that indicates the percentage of profit a company earns in relation to its overall resources. It is calculated by dividing net income by total assets.My Equities
My Current Equities and Potential Positions
| Entrada Therapeutics | TRDA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 18.8
Check out Entrada Therapeutics Performance and Entrada Therapeutics Correlation. For information on how to trade Entrada Stock refer to our How to Trade Entrada Stock guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Entrada Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.